Document is current
Any future updates will be listed below
-
Authors
Yu, Haichuan
Li, Yiming
Mo, Gaozhi P.
Luo, Zhe
Zarbock, Alexander
Fuhrman, Dana
Kang, Yan
Chen, Dechang
Rimmelé, Thomas
Prowle, John
Murray, Patrick
Srisawat, Nattachai
De Backer, Daniel
Premuzic, Vedran
Basu, Rajit K.
Ronco, Claudio
Ostermann, Marlies https://orcid.org/0000-0001-9500-9080
Kashani, Kianoush
Kellum, John A.
Peng, Zhiyong
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China
- License Information
-
More Information
Article History
Received: 1 February 2026
Accepted: 30 June 2026
First Online: 28 July 2026
Declarations
Conflicts of interest: All other authors declare no competing interests. MO has received research funding from Biomerieux and Baxter (paid to institution). JAK discloses the following: Employment/stock: Spectral Medical; Consultancy: AstraZeneca, Bayer, Chugai Pharma, Mitsubishi Tenabe; Licensed patents held by the University of Pittsburgh: Cytosorbents, J3RM. AZ has received consulting fees from Astute-Biomerieux, Baxter, Revelation, Dropshot Therapeutics, Chugai, Bayer, Novartis, Guard Therapeutics, AM Pharma, Paion, Viatris and Fresenius, and research funding from Astute-Biomerieux, DFG, Fresenius and Baxter, and speaker fees from Astute-Biomerieux, Fresenius, Baxter, Paion and Viatris. TR has received consulting and speaker fees from Biomerieux, Vantive and Fresenius Medical Care.
